GNAO1 and Parkinson disease: To conclude, caffeine and istradefylline have emerged as candidate pharmacological treatments for GNAO1-related MD; the potential clinical suitability of these drugs is strongly supported by their well-characterized safety, being already available for the treatment of primary apneas in premature newborns (59) and PD (45), respectively.